Short attack targets one of the favorites now sharing the lead in the popular KRAS drug development race

Sahm Adrangi?s short-attack team at Kerrisdale is out to slam one of the most popular biotech plays in the book this morning. The target is Mirati $MRTX, which has swiftly built a multibillion-dollar valuation around the idea that it can rival Amgen in an historic race to the market with…